Episode

Novo Nordisk's CEO Has a Comeback Plan

Podcast
The Journal.
Published
May 26, 2026
Duration seconds
1319
Processing state
not_requested
Canonical source
https://pdst.fm/e/traffic.megaphone.fm/WSJ3278290128.mp3?updated=1779828034
Audio
https://pdst.fm/e/traffic.megaphone.fm/WSJ3278290128.mp3?updated=1779828034
JSON
/v1/public/podcasts/the-journal-547598/episodes/novo-nordisk-s-ceo-has-a-comeback-plan
Markdown
/podcast/the-journal-547598/novo-nordisk-s-ceo-has-a-comeback-plan.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-journal-547598/episodes/novo-nordisk-s-ceo-has-a-comeback-plan/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-journal-547598/novo-nordisk-s-ceo-has-a-comeback-plan.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night. Further Listening: - Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out? - Trillion Dollar Shot Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices